Industry concerned about Indian regulator's timelines and lack of pharma expertise
This article was originally published in Scrip
Executive Summary
Even as India's revised competition regulations, which aim to regulate large M&A deals, became effective last week, pharmaceutical industry leaders and dealmakers say they are concerned about the potentially inadequate domain expertise at the regulator and the time lines that have been put in place to scrutinise such transactions.